SCHEMBL6891437

SCHEMBL6891437

Nc1cc(N2Cc3[nH]c(=O)[nH]c(=O)c3C2)nc2c(-c3cnc4ccccc4c3)cnn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PIK3CA P42336 4/20 0.36
TOP2A P11388 1/20 0.36
TOP2B Q02880 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6892783 0.82 CHEK1 (0.44) CHEK1CCNA2CDK2CCNA1PIM1
SCHEMBL10239462 0.81 KDM4E (0.37) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL2680935 0.77 PARP10 (0.41) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL30736 0.77 ATR (0.49) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL7874628 0.76 KDM4E (0.37) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL6894450 0.75 CRBN (0.42) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL6894420 0.74 PIK3CA (0.36) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL6891509 0.74 NEK2 (0.42) MAPK1KDM4EMEN1NPC1ALDH1A1
SCHEMBL6894488 0.73 CRBN (0.44) MAPK1KDM4EMEN1NPC1ALDH1A1
Formic Acid SCHEMBL2680174 0.73 PARP10 (0.38) MAPK1KDM4EMEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054013-A1 TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 MAPK1 2932/4885KDM4E 3091/4885MEN1 3300/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR MAPK1 277/4885KDM4E 1448/4885MEN1 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.